Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/16/2005EP1594500A1 Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones
11/16/2005EP1594499A1 Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
11/16/2005EP1594498A2 Methods and compositions for the treatment of degenerative ocular pathologies
11/16/2005EP1594496A2 Novel therapeutic method and compositions for topical administration
11/16/2005EP1594494A1 Oxazolidinone derivatives n-substituted by a bicyclic ring, for use as antibacterial agents
11/16/2005EP1594493A2 Polymorphic forms of tegaserod base and salts thereof
11/16/2005EP1594492A2 Novel inhibitors of formation of advanced glycation endproducts (ages)
11/16/2005EP1594491A1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
11/16/2005EP1594490A2 Treating androgen deficiency in female (adif)-associated conditions with sarms
11/16/2005EP1594489A2 A method of treating breast cancer with androgen receptor antagonists
11/16/2005EP1594488A2 Stabilized pharmaceutical compositions of safingol and methods of using the same
11/16/2005EP1594487A1 Composition comprising cysteamine for improving immunity of animals
11/16/2005EP1594486A2 Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same
11/16/2005EP1594485A2 Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use
11/16/2005EP1594484A2 Pharmaceutical patch
11/16/2005EP1594481A2 Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents
11/16/2005EP1594480A1 Method to treat chronic heart failure and/or elevated cholesterol levels
11/16/2005EP1594479A1 Stable oral benzimidazole compositions and processes for their preparation
11/16/2005EP1594474A2 Coated particles and pharmaceutical dosage forms
11/16/2005EP1594473A2 Composition and method for treating age-related disorders
11/16/2005EP1594472A1 Drug delivery from embolic agents
11/16/2005EP1594471A1 Dexamethasone-containing formulations for oral administration as well as the process for manufacturing required therefor
11/16/2005EP1594470A2 Rapid absorption selective 5-ht agonist formulations
11/16/2005EP1594465A2 Compositions comprising a plurality of particles or agglomerates having a defined particle size
11/16/2005EP1594464A2 Compositions comprising a defined polysaccharide component
11/16/2005EP1594463A2 Compositions comprising a polysaccharide component and one or more coating layers
11/16/2005EP1594462A1 Surgical implant compprising an anabolic and a corticosteroid
11/16/2005EP1594456A1 Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions
11/16/2005EP1594441A2 Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
11/16/2005EP1594440A2 The selective and specific preparation of discrete peg compounds
11/16/2005EP1594439A2 REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
11/16/2005EP1594435A2 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
11/16/2005EP1594433A2 Cancer therapy sensitizer
11/16/2005EP1594432A2 Short immunomodulatory oligonucleotides
11/16/2005EP1594371A1 Compositions containing creatine, creatinine and a methyl xanthine
11/16/2005EP1594366A2 Fat substitutes
11/16/2005EP1567173A4 A protectant for uv-induced skin damage
11/16/2005EP1496895B1 Use of cyclopamine in the treatment of psoriasis and other skin disorders
11/16/2005EP1492795B1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
11/16/2005EP1487472A4 Stabilization of hypoxia inducible factor (hif) alpha
11/16/2005EP1476429B1 Novel pyridine- and quinoline-derivatives
11/16/2005EP1463823A4 Methods of increasing endogenous erythropoietin (epo)
11/16/2005EP1461036A4 Bis hydrochloride monohydrate salt of rsv fusion inhibitor
11/16/2005EP1450782B1 Use of a combination composition comprising propionyl l-carnitine and further drugs for the treatment of erectile dysfunction
11/16/2005EP1416949A4 Method for isolating terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of ginkgo biloba
11/16/2005EP1409488B1 Imidazo-triazine derivatives as ligands for gaba receptors
11/16/2005EP1397129B1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/16/2005EP1379516B1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists
11/16/2005EP1379138B1 Liquid formulations for dermal application in treatment of parasitic insects in animals
11/16/2005EP1370557B1 Benzimidazole anti-inflammatory compounds
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1363623B1 Peptide deformylase inhibitors
11/16/2005EP1363608B1 Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleep disturbances
11/16/2005EP1357955B1 Drug delivery from stents
11/16/2005EP1347982B1 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
11/16/2005EP1345611A4 An antibiotic/analgesic formulation and a method of making this formulation
11/16/2005EP1331919A4 Dental composition for hypersensitive teeth
11/16/2005EP1317442B1 Quinolinone derivatives as tyrosine kinase inhibitors
11/16/2005EP1317426B1 Beta-thio-amino acids
11/16/2005EP1315724B1 A thiazolidinedione derivative and its use as antidiabetic
11/16/2005EP1299085B1 Improved liposomal camptothecins and uses thereof
11/16/2005EP1299084B1 Liposomal antineoplastic drugs and uses thereof
11/16/2005EP1292320B1 Use of extracts from spermatophyte plants with immunomodulating activity
11/16/2005EP1292319B1 Extracts from spermatophyte plants with antitumor activity
11/16/2005EP1289517B1 Pharmaceutical compositions comprising cannabidiol derivatives
11/16/2005EP1274459B1 Sustained release formulations comprising growth hormone
11/16/2005EP1267807B1 The use of prostaglandin F analogs for the preparation of compositions for the treatment of hair loss.
11/16/2005EP1257550B1 Platelet adp receptor inhibitors
11/16/2005EP1248768B1 Bile acid-substituted phenyl-alkenoylguanidines, method for producing said phenyl-alkenoylguanidines, use thereof as medicaments or diagnostic reagents and medicaments containing the same
11/16/2005EP1239824B1 Scar treatment composition comprising a silicone mixture
11/16/2005EP1237543B1 Effervescent histamine h2 antagonist composition
11/16/2005EP1222191B1 Benzodiazepin derivatives, the production and use thereof
11/16/2005EP1222182B1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
11/16/2005EP1220663B1 Superficial therapeutic system for topically applying acetylsalicylic acid, for the treatment of acne-related diseases
11/16/2005EP1220661B1 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid
11/16/2005EP1218374B1 Pharmaceutically active sulfonamide derivatives
11/16/2005EP1218017B1 Combination of a statin and ex-vivo treated blood for treating atherosclerosis
11/16/2005EP1216036B1 Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines
11/16/2005EP1212097B1 Enzyme inhibitors
11/16/2005EP1207886B1 Sphingomyelinase inhibitors as agents with antiapoptotic and antiseptic action
11/16/2005EP1147085B1 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
11/16/2005EP1146035B1 Crystal polymorphism of aminoethylphenoxyacetic acid derivative
11/16/2005EP1131090B1 Use of paraoxanase-1 (pon-1) to decrease atheroma formation and hypercholesterolemia
11/16/2005EP1114052B1 4-aminopyrrolopyrimidines as kinase inhibitors
11/16/2005EP1107767B1 Use of selenium for treating systemic inflammatory response syndrome (sirs), and composition for implementing said treatment
11/16/2005EP1068328B1 Treatment and diagnosis of staphylococcal infections
11/16/2005EP1066832B1 Preventives and remedies for ischemic reflow disorder
11/16/2005EP1007066B1 Screening methods for glucocorticoid receptor binding substances using trypterygium wilfordii preparations
11/16/2005EP1003522B1 Use of estrogen for preventing or controlling cataract
11/16/2005EP0981517B1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides
11/16/2005EP0979089B1 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
11/16/2005EP0977738B1 Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer
11/16/2005EP0923378B1 Promotion of wound healing by chemically-modified tetracyclines
11/16/2005EP0923370B1 Acetyl choline esterase inhibitors for treating and diagnosing sleep disordered breathing
11/16/2005EP0904099B1 Pharmaceutical formulation containing human growth hormone, histidine and a non-ionic detergent
11/16/2005EP0873406B1 Protein induced by deprenyl
11/16/2005EP0871703B1 Dna encoding glutamate gated chloride channels
11/16/2005EP0832232B1 Kunitz type plasma kallikrein inhibitors
11/16/2005EP0766538B1 Subcutaneous implant
11/16/2005CN1697836A Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists
1 ... 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 ... 7860